STR technology available for antibodies generated from OmniAb platform
OmniAb have entered into a licensing agreement for STR. The agreement provides OmniAb with exclusive, sublicensable access to ...
Read More Geoff Hale confirmed as keynote speaker at AET 2023
Our CEO, Geoff Hale, has been confirmed as a keynote speaker at Antibody Engineering and Therapeutics 2023 in ...
Read More Use of STR in an Fc fusion protein being developed for COVID-19 published
Dr. Neil Bodie and colleagues at Paradigm Immunotherapeutics along with collaborators at Kyoto University and Michigan State University ...
Read More Genscript ProBio licences STR technology from mAbsolve
Genscript ProBio have licenced mAbsolves first in class solution for abolising antibody effector function to enable their worldwide ...
Read More Geoff Hale to present at Promega Biologics Symposium
On Thursday 22nd September, our CEO, Geoff Hale, will be presenting some of our recent work on the ...
Read More mAbsolve publish paper in mAbs
Today our CEO and CSO, Geoff Hale and Ian Wilkinson, have had a new article published in mAbs. ...
Read More Ian Wilkinson to give webinar to Chinese Antibody Society
On Saturday 10th September our CSO, Ian Wilkinson, will be giving a webinar to the Chinese Antibody Society ...
Read More Patent granted for mAbsolve’s Fc silencing technology
On 5 Jul 2022 the UK Intellectual Property Office granted Patent number GB2595299 to mAbsolve. Publication of the ...
Read More Scancell license STR technology
Scancell, a UK based company developing anti-glycan antibodies, have today announced an agreement with mAbsolve to license our ...
Read More